Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB04 is a topical neurocosmetic product developed by Prospera Biotech for the management of intimate sensitivity, vaginal dryness, and itching. Marketed under the brand name Vagisens, it utilizes a proprietary peptide-based technology (HM-peptides) designed to modulate the activity of Transient Receptor Potential (TRP) channels, specifically the TRPV1 channel, on sensory nerve endings in the vulvovaginal mucosa. By desensitizing these channels, PB04 helps to alleviate the discomfort, burning, and itching sensations associated with vaginal hypersensitivity. It is part of a line of sensory-targeted products developed by Prospera Biotech, a spin-off from the Miguel Hernández University of Elche, focusing on neuro-dermatology and the treatment of skin and mucosal discomfort through sensory neuron modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PB04.